[{"orgOrder":0,"company":"Burke Neurological Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vitamin B1","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Burke Neurological Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Burke Neurological Institute \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Burke Neurological Institute \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Vitamin B1

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Burke Neurological Institute

                          Country arrow
                          Fi Europe 2024
                          Not Confirmed

                          Burke Neurological Institute

                          Country arrow
                          Fi Europe 2024
                          Not Confirmed

                          Details : Benfotiamine is a synthetic version of vitamin B1 (thiamine), which is being evaluated as a treatment for mild cognitive impairment and early Alzheimer's disease.

                          Brand Name : Benfotiamine

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 23, 2024

                          Lead Product(s) : Vitamin B1

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank